These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10630538)

  • 1. Complete reversibility of severe nucleoside-induced lipodystrophy.
    Strobel M; Muller P; Claudel P
    AIDS; 1999 Dec; 13(18):2606-7. PubMed ID: 10630538
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
    Shalit P; Farrell P; Lindgren P
    AIDS; 2001 Apr; 15(6):804-5. PubMed ID: 11371699
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors.
    Morris AA; Baudouin SV; Snow MH
    AIDS; 2001 Jan; 15(1):140-1. PubMed ID: 11192863
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy.
    Saint-Marc T; Touraine JL
    AIDS; 1999 Oct; 13(15):2188-9. PubMed ID: 10546885
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
    Villalba N; Gómez-Cano M; Casas E; Soriano V; Valencia E; González-Lahoz J
    AIDS; 1997 Dec; 11(15):1896-7. PubMed ID: 9412717
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
    Braitstein P; Chan K; Beardsell A; McLeod A; Montaner JS; O'Shaughnessy MV; Hogg RS
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):547-8. PubMed ID: 11981375
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophy and long-term therapy with nucleoside reverse transcriptase inhibitors.
    Moreno S; Martínez E
    AIDS; 2000 May; 14(7):905-6. PubMed ID: 10839605
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.
    Mateo MG; Gutierrez Mdel M; Vidal F; Domingo P
    Expert Opin Drug Saf; 2012 May; 11(3):473-85. PubMed ID: 22468613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
    Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
    Giaquinto C; De Romeo A; Giacomet V; Rampon O; Ruga E; Burlina A; De Rossi A; Sturkenboom M; D'Elia R
    AIDS; 2001 May; 15(8):1074-5. PubMed ID: 11399997
    [No Abstract]   [Full Text] [Related]  

  • 14. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
    Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
    [No Abstract]   [Full Text] [Related]  

  • 15. Developing countries need better antiretroviral drugs.
    Mykén N; Sundbeck B; Mpumilwa G; Andersson R
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):23-4. PubMed ID: 19171914
    [No Abstract]   [Full Text] [Related]  

  • 16. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactic acidosis secondary to nucleoside analogue antiretroviral therapy.
    Khouri S; Cushing H
    AIDS Read; 2000 Oct; 10(10):602-6. PubMed ID: 11068807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice.
    Yozviak JL; Doerfler RE; Woodward WC
    HIV Clin Trials; 2001; 2(6):474-6. PubMed ID: 11742435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
    Aldeen T; Wells C; Hay P; Davidson F; Lau R
    AIDS; 1999 May; 13(7):865-7. PubMed ID: 10357391
    [No Abstract]   [Full Text] [Related]  

  • 20. Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis.
    Schiano TD; Lissoos TW; Ahmed A; Siano C; Zaitman D; Cohn G; Ehrenpreis ED
    Am J Gastroenterol; 1997 Sep; 92(9):1563-4. PubMed ID: 9317091
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.